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Summary
Background: Chronic exposure to nicotine elicits physical
dependence in smokers, yet the mechanism and neuroana-
tomical bases for withdrawal symptoms are unclear. As in
humans, rodents undergo physical withdrawal symptoms after
cessation from chronic nicotine characterized by increased
scratching, head nods, and body shakes.
Results: Here we show that induction of physical nicotine
withdrawal symptoms activates GABAergic neurons within
the interpeduncular nucleus (IPN). Optical activation of IPN
GABAergic neurons via light stimulation of channelrhodopsin
elicited physical withdrawal symptoms in both nicotine-naive
and chronic-nicotine-exposed mice. Dampening excitability
of GABAergic neurons during nicotine withdrawal through
IPN-selective infusion of an NMDA receptor antagonist or
through blockade of IPN neurotransmission from the medial
habenula reduced IPN neuronal activation and alleviated with-
drawal symptoms. During chronic nicotine exposure, nicotinic
acetylcholine receptors containing the b4 subunit were upre-
gulated in somatostatin interneurons clustered in the dorsal
region of the IPN. Blockade of these receptors induced
withdrawal signs more dramatically in nicotine-dependent
compared to nicotine-naive mice and activated nonsomatos-
tatin neurons in the IPN.
Conclusions: Together, our data indicate that therapeutic
strategies to reduce IPN GABAergic neuron excitability during
nicotine withdrawal, for example, by activating nicotinic
receptors on somatostatin interneurons, may be beneficial
for alleviating withdrawal symptoms and facilitating smoking
cessation.
Introduction
Adverse health consequences caused by smoking kills
approximately 6 million people annually, making nicotine
addiction the primary cause of preventable mortality in the
world [1]. Smokers attempting to quit face a variety of
withdrawal symptoms that oftentimes drive relapse [2]. As in
humans, rodents chronically exposed to nicotine exhibit so-
matic (physical) and affective withdrawal symptoms [3]. Ro-
dent somatic symptoms include increased scratching, head
nods, and body shakes [4, 5], whereas affective symptoms
include anxiety and aversion [6]. The initiation and expression
of withdrawal is dependent on neuronal nicotinic acetylcholine
receptors (nAChRs) as symptoms can be precipitated by
administration of nicotinic receptor antagonists during chronic
nicotine exposure [7]. While the neurocircuitry underlying*Correspondence: andrew.tapper@umassmed.eduwithdrawal remains to be completely elucidated, the habenu-
lar-interpeduncular axis has recently been implicated in nico-
tine intake and aversion [8, 9]. Interestingly, direct infusion
of a nonspecific nAChR antagonist, mecamylamine, into
the interpeduncular nucleus (IPN) can precipitate somatic
withdrawal in nicotine-dependent mice, suggesting that the
habenular-interpeduncular axis may be important for the
expression of somatic signs of nicotine withdrawal. In addi-
tion, knockout mice that do not express nAChR a2, a5, or b4
subunits, which are particularly abundant in the IPN, exhibit
fewer somatic symptoms during nicotine withdrawal [10, 11].
However, whether the IPN is activated or inhibited after
chronic nicotine cessation or is sufficient to trigger somatic
or affective withdrawal symptoms is unknown.
Results
GABAergic Neurons in the IPN Are Activated during
Nicotine Withdrawal
To determine the effects of nicotine withdrawal on neurons
within the IPN, we treated C57BL/6J mice chronically with
nicotine via nicotine-laced drinking water (200 ml/ml) to induce
dependence. Control mice received water containing an
equivalent concentration of tartaric acid (see the Experimental
Procedures and Figure 1A). To precipitate withdrawal, mice
were challenged with mecamylamine (1 mg/kg, intraperitoneal
[i.p.]) or saline. Confirming that chronic nicotine exposure was
sufficient to induce nicotine dependence, somatic physical
withdrawal symptoms including scratching, body shakes,
and head nods, as well as total withdrawal symptoms, were
significantly increased in nicotine-treatedmice after mecamyl-
amine injection compared to nicotine-treated mice that
received a saline injection (Figures 1B and 1C). In addition,
the number of symptoms did not differ between nicotine-naive
mice that received mecamylamine or saline injection. Meca-
mylamine-precipitated withdrawal in nicotine-dependent
mice was also anxiogenic as mice undergoing withdrawal
buried more marbles in the marble-burying test (MBT) and
spent less time in the open arms of the elevated plus maze
(EPM) compared to nicotine-naive mice (Figures 1D and 1E).
Increased anxiety was not an artifact of decreased locomotor
activity as total arm entries in the EPM did not significantly
differ between groups (Figure 1F). To test the hypothesis that
neurons within the IPN were activated during nicotine with-
drawal, we immunolabeled IPN slices for c-Fos, a molecular
marker of neuronal activation [12], and glutamic acid decar-
boxylase 2/1 (GAD2/1), a marker of GABAergic neurons as
the IPN is a GABAergic neuron-rich brain region (Figure S1A
available online) [13]. Interestingly, mecamylamine induced
c-Fos expression predominantly in chronic-nicotine-treated
animals (Figures 2A and 2B). Two-way ANOVA revealed a
significant effect of chronic treatment (F1,16 = 53.23, p <
0.001) and drug (F1,16 = 124.5, p < 0.001) and a significant
chronic treatment 3 drug interaction (F1,16 = 51.70, p <
0.0001). Post hoc analysis indicated that the number of
c-Fos-immunoreactive (ir) neurons was significantly increased
after mecamylamine injection compared to saline injection in
nicotine-dependent (p < 0.001), but not nicotine-naı¨ve, mice.
Figure 1. Mecamylamine Precipitates With-
drawal in Nicotine-Dependent Mice
(A) Experimental strategy for inducing nico-
tine dependence/withdrawal in C57Bl/6J mice,
quantifying symptoms, and perfusing brains for
immunohistochemistry experiments illustrated
in Figure 2.
(B) Averaged total somatic withdrawal signs in
control and nicotine-treated animals after saline
or mecamylamine (1 mg/kg, i.p., n = 5 mice/treat-
ment) injection. Two-way ANOVA showed a sig-
nificant effect of chronic treatment (F1, 16 =
25.79, p < 0.0001) and drug (F1, 16 = 18.16, p <
0.001) and a significant interaction (F1, 16 = 9.69,
p < 0.01).
(C) Averaged number of individual nicotine with-
drawal symptoms from (A). Two-way ANOVA
showed the following: scratches, significant ef-
fect of drug (F1,16 = 17.39, p < 0.001) and chronic
treatment (F1, 16 = 13.2, p < 0.01); body shakes,
significant effect of drug (F1,16 = 26.64, p <
0.001), chronic treatment (F1, 16 = 24.63, p <
0.001), and interaction (F1, 16 = 12.77, p < 0.01);
and head nods, significant effect of drug (F1,16 =
31.74, p < 0.001), chronic treatment (F1, 16 =
29.93, p < 0.001), and interaction (F1, 16 = 24.81,
p < 0.001).
(D) Average number of marbles buried in
the MBT in control and nicotine-treated ani-
mals after saline or mecamylamine injection
(n = 7–24 mice/treatment). Two-way ANOVA
showed a significant effect of chronic treat-
ment (F1, 57 = 7.93, p < 0.01) but not drug, as
well as a significant interaction (F1, 57 = 8.47,
p < 0.01).
(E) Average time spent in the open arms of the EPM in mice (n = 7–10) treated as in (D). Two-way ANOVA showed a significant effect of drug (F1, 31 =
12.79, p < 0.01).
(F) Average total arm entries in the EPM in mice from (E).
Error bars indicate the SEM. *p < 0.05, **p < 0.01, ***p < 0.001, Bonferroni post hoc test.
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dent animals that received mecamylamine was significantly
greater than the number of c-Fos-ir neurons in nicotine-naive
animals receiving mecamylamine (p < 0.001). Colocalization
of c-Fos with GAD expression in mecamylamine-injected
nicotine-dependent mice occurred in >80% of neurons (Fig-
ure 2A, insets). Together, these data suggest that mecamyl-
amine-precipitated withdrawal induces activation of primarily
GABAergic neurons in the IPN.
To test whether excitability of IPN neurons would increase
during spontaneous nicotine withdrawal, we treated mice
chronically with nicotine (or control solution) as above. Spon-
taneous withdrawal was then elicited by replacement of
the nicotine drinking solution with water. Twenty-four hours
after nicotine cessation, brains were sliced, and whole-cell
voltage-clamp recordings were made in IPN neurons to mea-
sure spontaneous excitatory postsynaptic currents (sEPSCs;
Figures 2C and 2D). EPSC analysis revealed that in compari-
son to the control, neurons within the IPN of withdrawn mice
had increased sEPSC frequency (t68.9 = 4.35, p < 0.001), but
not amplitude, indicating increased excitatory input elicited
by increased release of glutamate in the IPN. GAD expression
(both GAD1 and GAD2) could be detected in >70% of neurons
as measured by single-neuron RT-PCR (Figure S1B).
Optical Activation of GAD2-Expressing IPN Neurons
Triggers Somatic Withdrawal Symptoms
To test the hypothesis that activation of GABAergic neurons
within the IPN was sufficient to elicit the observed nicotinewithdrawal symptoms, we selectively expressed channelrho-
dopsin with an eYFP tag (ChR2-eYFP) in the IPN of GAD2-
Cre mice using AAV2-mediated gene delivery of a plasmid
containing ChR2-eYFP in a double inverted open reading
frame (Figure S2A) [14, 15]. Four to six weeks postinfection,
significant eYFP signal was observed in GAD2/1-expressing
neurons, indicating proper localization to GABAergic neurons
(Figure S2B). Light stimulation of ChR2-eYFP-positive neurons
in IPN midbrain slices from ChR2-eYFP-infected GAD2-Cre
mice elicited robust trains of action potentials, whereas neu-
rons from control animals did not respond to light (Figure S2C).
These data confirmed that ChR2-eYFP was expressed and
functional within the IPN.
For activation of GABAergic neurons in vivo, GAD2-Cremice
were infected with AAV2 ChR2-eYFP or control (AAV2-eGFP)
virus and optic cannulas were implanted targeting the IPN in
both chronic-nicotine-treated and nicotine-naive GAD2-Cre
mice 4–6 weeks postinfection. Blue light (via 473 nM LED)
was delivered to the IPN in vivo, and somatic withdrawal
symptoms were scored (Figure 3). Ten pulses of light at
50 Hz were delivered every 5 s for 10 min (Figure 3A). This light
stimulation protocol was used to induce phasic firing of these
neurons [16–18], a stimulation that is also sufficient to induce
c-Fos expression [19], mimicking what is observed during
mecamylamine-precipitated withdrawal. Light delivery into
the IPN elicited significant withdrawal-like symptoms in
chronic-nicotine-treated, ChR2-eYFP-expressing GAD2-Cre
mice, including scratching (p < 0.05), body shakes (p <
0.001), and head nodding (p < 0.001), compared to light
Figure 2. Nicotine Withdrawal Activates IPN GABAergic Neurons
(A) Representative photomicrographs of IPN slices immunolabeled for GAD2/1 (green, top) and c-Fos (red,middle) from control or nicotine-treatedmice that
received saline (Sal) or mecamylamine (Mec) injections as indicated. The bottom panels depict merged signals. Insets show 6303 magnification images.
Colocalization of c-Fos in GAD-immunopositive neurons was apparent after mecamylamine injections. Note that a similar pattern of c-Fos labeling after
mecamylamine challenge was observed in the IPN of mice that self-administer nicotine in a 24 hr two-bottle choice assay (data not shown).
(B) Average number of c-Fos-immunoreactive (ir) IPN neurons under each condition from (A) (n = 5 mice/treatment). Two-way ANOVA and Bonferroni post
hoc test were performed.
(C) Representative whole-cell recordings illustrating sEPSCs from IPN neurons of control mice (left) and nicotine-withdrawn mice (right).
(D) Average sEPSC frequency (left) and amplitude (right) in IPN neurons of control (n = 26 neurons/treatment) and nicotine-withdrawn mice (n = 45 neurons/
treatment).
Error bars indicate the SEM. Student’s t test with Welch’s correction. ***p < 0.001. See also Figure S1.
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2329delivery in control mice, which elicited few symptoms (Fig-
ure 3A). A similar phenotype was also observed in nicotine-
naive animals (Figure S3). To determine whether activation of
the same neurons within the IPN also triggered the anxiogenic
effects of withdrawal, we stimulated neurons as described
above and measured anxiety-like behavior in the EPM and
MBT assays (Figure 3B). Time spent in the open arms of the
EPM, as well as total arm entries, did not differ between
ChR2-eYFP-expressing GAD2-Cre mice and control animals
during light stimulation. Similarly, the number of marbles
buried in the MBT was not significantly different in ChR2-
eYFP-expressing GAD2-Cre mice at baseline (without light
stimulation) compared to during light stimulation. To measure
expression and function of ChR2-eYFP in infected animals, we
isolated brains after light stimulation and verified eYFP expres-
sion under fluorescence microscopy (Figure 3C). In addition,
the number of c-Fos-ir IPN neurons in ChR2-eYFP-infected
mice was significantly greater after light stimulation compared
to controls, indicating neuronal activation by light stimulus
(Figures 3C and 3D; p < 0.001).
Glutamate Release from MHb-IPN Afferents Is Necessary
for Somatic Nicotine Withdrawal Signs
We next explored the potential mechanism underlying activa-
tion of IPN GABAergic neurons during nicotine withdrawal. To
test the hypothesis that increased glutamate release in the
IPN during nicotine withdrawal is necessary for the observed
increase in neuronal activation, we infused saline or an NMDA
receptor antagonist, AP5, prior to infusion of mecamylamine,
directly into the IPN of control and chronic-nicotine-dependent
mice followed by c-Fos analysis (Figures 4A and 4B). Two-wayANOVA indicated a significant effect of chronic treatment
(F1,10 = 52.45, p < 0.0001) and infusion (F1,10 = 37.43, p <
0.0001) and a significant chronic nicotine3 infusion interaction
(F1,10 = 12.97, p < 0.01). Post hoc analysis revealed that infusion
of mecamylamine into the IPN was sufficient to increase
the number of c-Fos-ir neurons in nicotine-dependent mice
compared to mecamylamine infusion in nicotine-naive animals
(p < 0.001). In addition, preinfusion of AP5 reduced the number
of c-Fos-ir neurons elicited by mecamylamine in nicotine-
dependent but not naiveanimals (p< 0.001). To test the hypoth-
esis that reducing activation of IPN neurons via an NMDA
antagonist could alleviate withdrawal symptoms, we infused
saline or AP5 directly into the IPN of nicotine-dependent mice
undergoing spontaneous withdrawal (Figure 4C). Saline infu-
sion did not affect withdrawal symptoms as symptoms were
significantly increasedcompared tobaseline responses (symp-
toms in nicotine-treated mice prior to cessation). In contrast,
AP5 infusion during spontaneous withdrawal significantly
decreased individual symptoms, including scratching and
body shakes, and the number of total symptoms compared to
a saline infusion (Figure 4C, inset). Aswe have done previously,
guide cannulas were verified to target the IPN in each animal
[20] (Figure S4A). Recent data indicate that cholinergic neuron
afferents projecting from the medial habenula (MHb) also syn-
thesize and release glutamate into the IPN [21]. To test the
hypothesis that MHb neurons provide the source of glutamate
that stimulates IPN neurons during withdrawal, we implanted
mice with cannulas targeting the MHb and infused lidocaine
to block neurotransmission during spontaneous nicotine with-
drawal [8] (Figures 4DandS4B). Lidocaine infusion significantly
blocked both individual and total somatic nicotine withdrawal
Figure 3. Activation of GABAergic Neurons Triggers Somatic Withdrawal Symptoms
(A) Top: schematic of experimental strategy and neuronal activation protocol. Bottom: averaged individual withdrawal symptom behaviors elicited by light
exposure in chronic-nicotine-treated GAD2-Cre mice infected with AAV2-eGFP (control, white bars) or AAV2-ChR2-eYFP (black bars; n = 7mice/condition).
Unpaired two-tailed t tests with Welch’s correction revealed that light stimulation induced a significant increase in scratching (t5.22 = 2.96), body shakes
(t6.54 = 18.2), head nods (t5.52 = 26.2), backings (t6.14 = 3.24), and other symptoms (t4.27 = 3.49) in AAV2-CHR2-eYFP-infected mice compared to AAV2-
eGFP-infected mice (n = 4–6 mice/group). Inset: total signs during light stimulation (unpaired two-tailed t test, t7 = 6.58).
(B) Average time spent in the open-arm (top left), closed-arm (top right), and total-arm entries (bottom left) in the EPM during light stimulation in nicotine-
treated GAD2-Cre mice infected with AAV2-eGFP or AAV2-CHR2-eYFP (n = 7–10 mice/group). The average number of marbles buried in the MBT in AAV2-
CHR2-eYFP-infected GAD2-Cre mice at baseline prior to light stimulation and during light stimulation is shown (bottom right; n = 11).
(C) Representative IPN sections fromAAV2-eGFP- and AAV2ChR2-eYFP-infectedmice after light stimulation. Sections were immunolabeled for c-Fos (red).
Insets show 6303 magnification images. Colocalization of c-Fos in eYFP-expressing neurons was apparent after light stimulation.
(D) Averaged total number of IPN c-Fos-ir neurons after light stimulation (t10 = 5.18).
Error bars indicate the SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S2 and S3.
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caine into the MHb prior to mecamylamine-precipitated with-
drawal also reduced neuronal activation of IPN neurons as
measured by c-Fos (Figure S5, p < 0.01).
IPN Sst Interneurons Express nAChRs Containing the b4
Subunit that Are Upregulated during Chronic Nicotine
Exposure
Both nicotine cessation andmecamylamine inducewithdrawal
symptoms, presumably by decreasing/blocking activity of
nAChRs. How might a decrease in activity of excitatory
nAChRs lead to neuronal activation? This scenario could occur
if nAChRs were prominently expressed in a population of
inhibitory interneurons, leading to disinhibition of projection
neurons or glutamate release from presynaptic terminals
upon reduced nAChR activity. To explore this possibility, we
examined nAChR expression and function in IPN somatostatin
(Sst) interneurons, a subpopulation of interneurons known toexist in the IPN [22] and shown to modulate glutamate release
from presynaptic terminals in other brain regions [23]. We laser
dissected Sst-immunopositive and -immunonegative IPN neu-
rons and compared nAChR subunit expression from nicotine-
dependent and nicotine-naivemice using quantitative RT-PCR
(Figure 5A). Interestingly, immunolabeling of Sst neurons
revealed that they are densely clustered within the very dorsal
region of the IPN (Figure 5A, insets). Expression of a2-a7 and
b2-b4 nAChR subunits was detected in both neuronal popu-
lations. Expression of b3 and b4 nAChR subunits was signifi-
cantly upregulated in Sst-immunopositive neurons from
chronic-nicotine-treated mice compared to nicotine-naive
animals (p < 0.05; Figure 5A, bottom), whereas only the a7 sub-
unit was modestly upregulated in Sst-immunonegative neu-
rons from chronic-nicotine-treated mice (Figure 5A, top). To
determine whether nAChRs in Sst neurons were functionally
upregulated after chronic nicotine exposure, we measured
whole-cell currents in response to nicotine in IPN slices from
Figure 4. Glutamatergic Signaling from MHb Projections Is Critical for IPN Neuronal Activation during Withdrawal and Expression of Somatic Withdrawal
Symptoms
(A) Representative IPN sections from control or chronic-nicotine-treated mice after IPN infusion of Sal + Mec or AP5 + Mec. Sections were immunolabeled
for GAD2/1 (red, top) and c-Fos (green, middle). The bottom panels depict merged signals. Insets show 6303 magnification images and colocalization of
c-Fos in GAD-immunopositive neurons.
(B) Averaged total number of c-Fos-ir IPN neurons for each condition in (A) (control mice, n = 3 mice/treatment; chronic-nicotine-treated mice, n = 4 mice/
treatment).
(C) Averaged number of individual spontaneous withdrawal signs in nicotine-dependent mice at baseline (prior to cessation), after IPN-infusion of saline, or
after IPN-infusion of AP5 (n = 6 mice/treatment). One-way repeated-measure ANOVA for each symptom indicated a significant main effect of infusion on
scratches (F2,10 = 13.65, p < 0.01), body shakes (F2,10 = 33.5, p < 0.001), head nods (F2,10 = 27.34, p < 0.001), backing (F2,10 = 4.15, p < 0.05), and others
(F2, 10 = 4.96, p < 0.05). Inset: average total number of withdrawal symptoms. One-way repeated-measures ANOVA indicated a significant main effect of
infusion on total number of symptoms (F2,10 = 30.73, p < 0.001).
(D) Averaged number of individual spontaneous withdrawal signs in nicotine-dependent mice undergoing spontaneous withdrawal after saline infusion
(white bars) or lidocaine infusion (black bars) into theMHb (n = 6mice/group). Unpaired two-tailed t tests revealed that lidocaine induced a significant reduc-
tion in scratching (t10 = 5.08), body shakes (t10 = 5.16), head nods (t10 = 8.64), and other symptoms (t10 = 10.33) compared to saline infusion. Inset: total with-
drawal symptoms after MHb saline or lidocaine infusions (unpaired two-tailed t test, t10 = 8.71).
Error bars indicate the SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S4 and S5.
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dorsal region of the IPN were targeted based on the observed
pattern of Sst immunolabeling. Neuronal identity was
confirmed by single-neuronal RT-PCR (Figure S6A). This anal-
ysis also revealed that Sst neurons predominantly express
GAD1, whereas GAD2 expression was detected in only ten
out of 43 (w23%) Sst-expressing neurons. Nicotine (10 mM)
elicited robust inward currents in IPN Sst neurons that were
modestly but significantly larger in slices from chronic-nico-
tine-treated mice (Figure 5B; w80% increase, p < 0.05). To
determine whether the nAChR subtype underlying responses
to nicotine in Sst IPN neurons contained, in part, the b4 sub-
unit, we measured nicotine-induced currents in the presence
of SR16584 (20 mM), an antagonist selective for nAChRs con-
taining the b4 subunit [24]. In nicotine-naive slices, SR16584
exhibited a trend to reduce currents induced by nicotine in
Sst neurons (w40% reduction), whereas in slices from nico-
tine-treated mice, SR16584 significantly and robustly reduced
nicotine-elicited currents (w75%, p < 0.01).
Blockade of b4 nAChR Signaling in the IPN Elicits Somatic
Nicotine Withdrawal Signs
To determine whether blockade of nAChRs containing the
b4 subunit could elicit somatic withdrawal symptoms inmice similar to mecamylamine, we infused SR16584 into
the IPN of nicotine-treated and control mice. SR16584
induced withdrawal-like symptoms in nicotine-naive animals
compared to saline infusion (predominantly rearing and other
symptoms; Figure 5C). However, SR16584 infusion induced
a greater number of individual symptoms (including head
nodding and body shaking) and a greater number of total
symptoms in chronic-nicotine-treated mice compared to
nicotine-naive animals, indicating a role for upregulation of
nAChRs containing the b4 subunit in physical withdrawal
symptoms (Figure 5D). Based on our hypothesis, we would
expect that blockade of b4 nAChRs would activate non-Sst
neurons within the IPN, triggering somatic withdrawal
symptoms. To test this hypothesis, we immunolabeled IPN
sections for c-Fos and Sst expression after IPN infusion of
SR16584 (Figure S6B). We were unable to detect c-Fos in
Sst-immunopositive neurons, whereas c-Fos was induced
by antagonist in Sst-immunonegative neurons. The number
of c-Fos neurons induced by SR16584 infusion was signifi-
cantly greater in both nicotine-naive and nicotine-treated
animals compared to a saline infusion. In addition, the
number of c-Fos-immunopositive neurons was significantly
greater in chronic-nicotine-treated mice compared to nico-
tine-naive mice.
Figure 5. A Role for Sst Interneuron nAChRs Containing the b4 Subunit in Somatic Nicotine Withdrawal Symptoms
(A) Comparison of nAChR subunit gene expression in Sst-immunonegative (top) and -immunopositive (bottom) neurons from the IPN of nicotine-naive and
chronic-nicotine-treated mice. Fold change was calculated using the 22DDCt method. The red dotted line represents equal gene expression between
nicotine-naive and chronic-nicotine-treated animals (n = 3 mice/group). Insets show representative photomicrographs of IPN sections immunolabeled
for Sst.White dotted lines represent regionswhere neuronswere laser-captured for each analysis. *p < 0.05 gene expression of nAChR subunit from nicotine
treated compared to control mice (unpaired t tests: a7, t4 = 3.13; b3, t4 = 3.85; b4, t4 = 2.94).
(B) Top: representative whole-cell currents in response to 10 mMnicotine (bath-applied, black bars) in IPN Sst neurons from nicotine-naive (left) and chronic-
nicotine-treated mice (right). Bottom: average peak currents from nicotine whole-cell responses in Sst neurons from nicotine-naive and chronic-nicotine-
treated mice in the absence (white bar) and presence (black bar) of SR16584. ^p < 0.05 compared to neurons from nicotine-naive mice (t26 = 1.89). **p < 0.01
compared to control responses in neurons from nicotine-treated mice (t20 = 3.02).
(C) Averaged number of individual spontaneous withdrawal signs in control and chronic-nicotine-treatedmice after IPN infusion of saline or SR16584 (n = 5–
8 mice/group). Two-way ANOVA showed the following: scratches, significant effect of antagonist (F1,19 = 7.52, p < 0.05) and chronic treatment (F1, 19 = 5.14,
p < 0.05); body shakes, significant effect of antagonist (F1,19 = 22.02, p < 0.001), chronic treatment (F1, 19 = 9.18, p < 0.01), and interaction (F1, 19 = 7.63, p <
0.05); head nods, significant effect of antagonist (F1,19 = 34.38, p < 0.001), chronic treatment (F1, 19 = 96.64, p < 0.001), and interaction (F1, 19 = 44.78, p <
0.001); rearing, significant effect of drug (F1,19 = 33.95, p < 0.001); and other symptoms, significant effect of antagonist (F1,19 = 62.72, p < 0.001).
(D) Average total withdrawal symptoms from (C). Two-way ANOVA indicated a statistically significant effect of antagonist (F1,19 = 9.09, p < 0.01) and chronic
treatment (F1,19 = 77.77, p < 0.001).
Error bars indicate SEM. *p < 0.05, **p < 0.01, ***p < 0.001, Bonferroni post hoc test. See also Figure S6.
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Here we show that withdrawal from chronic nicotine treatment
activates GABAergic neurons of the IPN. GABAergic neuronal
activation during withdrawal is mediated, at least in part, by
enhancement of excitatory input as EPSC frequencies, but
not amplitudes, were increased in GABAergic neurons from
nicotine-withdrawn mice compared to nicotine-naive animals.
These data suggest increased glutamate release mediates
enhanced activation of IPN GABAergic neurons during nico-
tine withdrawal. Dampening excitability of IPN GABAergic
neurons using anNMDA receptor antagonist reduced neuronal
activation and alleviated withdrawal symptoms, suggesting
that increased glutamate release into the IPN is necessary
for expression of somatic withdrawal symptoms. The IPN
receives robust input from cholinergic neurons of the
MHb [25]. Recent data indicate that these same inputs alsosynthesize and release glutamate [21]. Consistent with this
idea, blocking neurotransmission of the MHb inhibited activa-
tion of the IPN during mecamylamine-precipitated nicotine
withdrawal and alleviated withdrawal symptoms. Enhanced
excitability of IPN GABAergic neurons is mediated by gluta-
matergic signaling whether withdrawal is precipitated by a
mecamylamine infusion or elicited by nicotine abstinence,
suggesting the mechanism is similar between both withdrawal
paradigms and likely involves decreased nAChR signaling.
Indeed, we identified Sst-immunopositive interneurons within
the dorsal region of the IPN that robustly expressed nAChRs.
Within this population of interneurons, chronic nicotine upre-
gulated gene expression of b3 and b4 nAChR subunits and
yielded more robust nicotine-induced currents that were sen-
sitive to a b4 nAChR antagonist. Interestingly, the b3 and b4
nAChR subunits coassemble in the IPN to form a unique
nAChR subtype [26]. IPN infusion of a b4 nAChR antagonist
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Figure 6. Mechanistic Model of Somatic Nicotine Withdrawal Symptom Expression
(A) The IPN receives glutamatergic input (Glu) from the MHb. Presynaptic glutamate release is controlled, in part, by Sst neurons, which express nAChRs.
Nicotine activates Sst neurons through nAChRs containing the b3 and b4 subunits (b3b4* nAChRs), inhibiting MHb glutamate release (red arrow). With
chronic nicotine exposure, these nAChRs are upregulated.
(B) During nicotine withdrawal, decreased nAChR signaling either through nicotine cessation or via nAChR blockade with an antagonist reduces Sst neuron
activation, disinhibiting glutamate release from MHb presynaptic terminals. The increased glutamate release stimulates activity of IPN GAD2-expressing
(presumably projection) neurons, eliciting somatic withdrawal signs.
(C) In the optogenetic experiments, ChR2 is expressed in GAD2-expressing neurons only. Light stimulation ultimately drives activation of these neurons
triggering somatic withdrawal signs.
IPN GABAergic Neurons in Nicotine Withdrawal
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mice and activated non-Sst IPN neurons, indicating a role for
b4 nAChRs in somatic nicotine withdrawal symptoms. These
data are in agreement with previous studies on b4 nAChR sub-
unit knockout mice, which fail to express somatic nicotine
withdrawal symptoms [11, 27]. To our knowledge, this is the
first report of a chronic-nicotine-mediated neuroadaptation
in the IPN.
Together, our data allow us to provide a mechanistic model
underlying expression of somatic nicotine withdrawal symp-
toms (Figure 6). GABAergic (presumably projection) neurons
within the IPN receive glutamatergic input from the MHb. Inhi-
bition of MHb glutamatergic terminals is modulated by Sst
interneurons clustered in the dorsal portion of the IPN, consis-
tent with the known effect of Sst interneurons in regulating
presynaptic glutamate release [23]. During chronic nicotine
exposure, nAChRs containing the b3 and b4 subunits are
upregulated in Sst interneurons to help increase drive of Sst
interneuron activity and offset (i.e., inhibit) glutamate release
from the MHb (Figure 6A). During spontaneous withdrawal or
mecamylamine-precipitated withdrawal, decreased nAChR
signaling reduces Sst interneuron activity, thereby disinhibit-
ing glutamate release from the MHb. The increased glutamate
release increases excitability of GABAergic neurons, thereby
eliciting somatic nicotine withdrawal symptoms (Figure 6B).
In this scenario, it is likely that a specific population of
GABAergic neurons (i.e., non-Sst GABAergic or projection
neurons) receive glutamatergic input from MHb projections,
whereas Sst neurons may receive MHb cholinergic input,
although additional experiments will be needed to test thishypothesis. In our optogenetic experiments, this mechanism
is bypassed: ChR2 is expressed in GAD2-expressing neurons,
which are predominantly non-Sst neurons as GAD2 was de-
tected in only a small fraction of Sst neurons. Optical activation
of GAD2-expressing IPN neurons directly triggers somatic
withdrawal-like symptoms regardless of nicotine exposure,
indicating that activation of these neurons is sufficient for
expression of somatic withdrawal behaviors (Figure 6C).
Interestingly, activation of IPN GAD2-expressing neurons
did not induce anxiety, suggesting that other brain regions
maymediate affective nicotine withdrawal symptoms. Alterna-
tively, distinct populations of neurons within the IPN may be
differentially involved in somatic and affective withdrawal
symptoms. Regardless, these data are consistent with previ-
ous studies indicating somatic and affective withdrawal
behaviors, at least in rats, are dissociable [28]. Future experi-
ments are underway to characterize IPN subregions and
neuronal subpopulation in the context of drug withdrawal
behaviors.
Together, our data are the first demonstrating direct
activation of a brain region eliciting physical withdrawal
symptoms. Additional brain regions have been implicated in
physical symptoms of nicotine withdrawal, including the
MHb (confirmed here) and, most recently, the paraventricular
nucleus of the hypothalamus, which also projects to the IPN
[10, 29–32]. Thus, the paraventricular nucleus may also be a
part of the neural network underlying nicotine somatic with-
drawal symptoms. Additional studies should focus on further
mapping this network in an effort to identify neuroanatomical
targets to reduce withdrawal symptoms. In summary, our
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2334data indicate that withdrawal from chronic nicotine activates
GABAergic neurons in the IPN. Activation of these neurons is
both necessary and sufficient for the induction of somatic
withdrawal symptoms. Reducing activation of these neurons,
through stimulating Sst interneuron nAChRs, for example,
may represent a potential novel therapeutic strategy to alle-
viate withdrawal symptoms during smoking cessation.
Experimental Procedures
Animals
Male C57BL/6J mice and GAD2-Cre mice (Jackson Laboratory) were used
in all experiments. GAD2-Cre mice have been described previously and
have been backcrossed to a C57BL/6J background for at least one gener-
ation [15]. Animals were kept on a standard 12 hr light/dark cycle with lights
on at 7:00 a.m. and off at 7:00 p.m. Behavioral experiments were performed
during the light cycle. Independent groups of animals were used for each
behavioral experiment unless otherwise noted. Mice were housed four per
cage and received food and drinking solution ad libitum. All experiments
were conducted in accordance with the guidelines for care and use of lab-
oratory animals provided by the National Research Council [33], as well as
with an approved animal protocol from the Institutional Animal Care and
Use Committee of the University of Massachusetts Medical School.
Drugs and Drinking Solution
Nicotine and control drinking solutions were prepared from nicotine
hydrogen tartrate or L-tartaric acid (Sigma-Aldrich), which were dissolved
in tap water with concentrations of 200 mg/ml and 300 mg/ml, respectively.
Saccharin Sodium (Fisher Scientific) was added to each solution to sweeten
the taste with a concentration of 3 mg/ml. Mecamylamine hydrochloride
(1 mg/kg, i.p.) was dissolved in sterile saline. For intra-IPN drug infusions,
mecamylamine (2 mg/ml) and AP5 (2 mg/ml) were dissolved in sterile saline.
SR 16584 (2.7 mg/ml) was dissolved in 50% dimethyl sulfoxide. For intra-
mHb drug infusion, lidocaine (10 mg/ml) was dissolved in sterile saline. Nico-
tine and mecamylamine doses are reported as free base.
Mecamylamine-Precipitated and Spontaneous Nicotine Withdrawal
Mice received chronic nicotine treatment via nicotine in the drinking water
(i.e., water and nicotine was received from a single bottle) beginning at
age 6 weeks. After 6 weeks of nicotine/control drinking solution and
3 days of habituation to saline i.p. preinjection, mice were injected (i.p)
with 1 mg/kg of mecamylamine or saline and were immediately put back
into their home cages. Somatic withdrawal signs were observed 2 min later
and recorded for 20 min. Typical signs include scratching, body shaking,
head nodding, backing, rearing, chewing, whichwere tabulated once/event.
‘‘Other’’ behaviors were defined as grooming, circling, jumping, cage
scratching, ptosis, and digging and were scored no more than one event
per minute. Ninety minutes postinjection, mice were perfused, and the
brains were removed for immunohistochemistry. For spontaneous with-
drawal, mice were treated with nicotine or control solution for 6 weeks as
above. For induction of spontaneous withdrawal, nicotine solution was
replaced with control solution. Withdrawal behaviors were measured
24 hr after nicotine cessation. Similar somatic withdrawal signs were
observed in mice receiving a 24 hr/day two-bottle choice test (nicotine
and control solution), indicating that withdrawal signs also occurred when
nicotine exposure was not ‘‘forced.’’
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